News
BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...
New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...
1d
TipRanks on MSNBioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer
The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is being compared against standard chemotherapy drugs, doxorubicin or paclitaxel, ...
BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...
The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results